Highlights from the Congress,
Tuesday, May 31
The Tuesday programme started off with a plenary session featuring new insights in lipid biology and continued with a workshop programme containing, amongst others, a joint EAS-ICCR session on management of cardiometabolic risk. The afternoon offered two EBAC accredited sessions and the EAS inititive session focused of the Society and it's activities offered to both members and non-members.
The Clinical Latebreaker session provided preliminary evidence with emerging treatments. According to lead author, Professor Daniel Gaudet, Montreal, Canada: "We are in a very exciting era for homozygous FH research with novel therapies emerging from genetic insights. As is the case for PCSK9, the rationale for the development of a novel monoclonal antibody targeting ANGPTL3 has been driven by family pedigrees which showed that individuals with loss of function ANGPTLS mutations had lower LDL cholesterol levels."
Read the report from the Clinical Latebreaker session >>
From the Plenary Programme
The focus of the presentations at Tuesday's plenary session was "Do novel insights from lipid biology offer therapeutic potential?" Professor Rudolf Zechner, Institute of Molecular Biosciences, University of Graz, Austria discussed whether lipolysis, specifically adipose triglyceride lipase (ATGL), may represent a potential target for the management of metabolic disease
Professor Jörg Heeren, University Medical Center Hamburg Eppendorf discussed that the possibility may involve targeting browning of WAT and Professor David Mangelsdorf, University of Texas Southwestern Medical Center, Dallas, USA talked about that fibroblast growth factor-21 (FGF21) as an endocrine growth factor, may offer exciting therapeutic possibilities.
To the full Tuesday sessions report >>
From the Workshop programme
Obesity and its associated complications of diabetes and fatty liver disease represent key challenges globally. According to the World Health Organization, obesity has more than doubled since 1980. Moreover, statistics for childhood obesity are even more frightening, with 42 million children under the age of 5 considered overweight or obese (2013 data). Yet obesity is preventable, as discussed in the Joint International Chair on Cardiometabolic Risk (ICCR) and EAS session.
While the search for novel treatment targets clearly has a role, Professor Jean Pierre Després, Québec, Canada made the case for refocusing on lifestyle: "The approach to cardiovascular disease management is inefficient and costly. We need to refocus on lifestyle approaches." Notably, four common lifestyle risk factors – smoking, excessive alcohol intake, poor diet and lack of physical activity – are associated with four disease clusters, cardiovascular disease, cancer, chronic pulmonary diseases, and diabetes, that account for about 80% of deaths from non-communicable disease.
Listen to Professor Després in an interview from the EAS congress >>
Read the full Tuesday sessions report >>